Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi, 329-0412, Japan.
BMC Vet Res. 2019 Aug 6;15(1):280. doi: 10.1186/s12917-019-2036-0.
Equine herpesvirus type 1 (EHV-1) infection is a major cause of pyrexias in winter among Japanese racehorses. In 2014-2015, the Japan Racing Association (JRA) changed the EHV-1 vaccine from an inactivated vaccine to a live vaccine (both produced by Nisseiken). To evaluate the effect of changing the vaccines, the capacities of these vaccines to induce virus-neutralizing (VN) antibodies were compared, and an epizootiological investigation of EHV-1 was performed at the JRA Ritto Training Center during epizootic periods from 2010-2011 to 2016-2017.
Three-year-old horses that received the first dose of live vaccine showed higher geometric mean (GM) VN titers (205 and 220) than those that received inactivated vaccine (83, P < 0.05). The response rates after vaccination with the live vaccine (76 and 90%) were higher than that after vaccination with inactivated vaccine (42%, P < 0.05). Four-year-old horses from 2015 to 2017 that had received the live vaccine in the previous epizootic periods had higher GM titers (205 to 246) than those from 2011 to 2014, which had received the inactivated vaccine (139 to 164, P < 0.05). The estimated numbers of horses infected with EHV-1 or EHV-4, or both, in 2011-2012 (29 [95%CI: 21-37]) and 2013-2014 (37 [95%CI: 27-47]) were higher than those in the other periods (7 [95%CI: 2-12] to 16 [95%CI: 9-23]). Likewise, the seroconversion rates to EHV-1 in horses that stayed at the training center in 2011-2012 (66.0%) and 2013-2014 (52.0%) were higher than those in the other periods (12.0 to 28.6%).
The live EHV-1 vaccine is highly immunogenic and provides greater VN antibody responses than the inactivated vaccine. Unlike the period when the policy was to use inactivated vaccine, there was no detectable epizootic EHV-1 infection at the training center during three consecutive periods after the introduction of the live vaccine. These results suggest that the replacement of inactivated vaccine with live vaccine, together with the achievement of high vaccination coverage, reinforced the herd effect, and contributed to better control of EHV-1 epizootics in the training center.
马疱疹病毒 1 型(EHV-1)感染是日本赛马冬季发热的主要原因。2014-2015 年,日本赛马协会(JRA)将 EHV-1 疫苗由灭活疫苗改为活疫苗(均由日新制薬生产)。为了评估疫苗更换的效果,比较了这两种疫苗诱导病毒中和(VN)抗体的能力,并在 2010-2011 年至 2016-2017 年流行期间,在 JRA 利托培训中心进行了 EHV-1 的流行病学调查。
首次接种活疫苗的 3 岁马的几何平均(GM)VN 滴度(205 和 220)高于接种灭活疫苗的马(83,P<0.05)。活疫苗接种后的反应率(76%和 90%)高于灭活疫苗接种后的反应率(42%,P<0.05)。2015 年至 2017 年,在前一个流行期接种过活疫苗的 4 岁马的 GM 滴度(205 至 246)高于 2011 年至 2014 年接种过灭活疫苗的马(139 至 164,P<0.05)。2011-2012 年(29 [95%CI:21-37])和 2013-2014 年(37 [95%CI:27-47])感染 EHV-1 或 EHV-4 或两者的马的估计数量高于其他时期(7 [95%CI:2-12] 至 16 [95%CI:9-23])。同样,2011-2012 年(66.0%)和 2013-2014 年(52.0%)留在培训中心的马的 EHV-1 血清转化率高于其他时期(12.0 至 28.6%)。
活 EHV-1 疫苗具有高度的免疫原性,能产生比灭活疫苗更高的 VN 抗体反应。与使用灭活疫苗的时期不同,在引入活疫苗后的连续三个流行期内,培训中心未检测到 EHV-1 流行感染。这些结果表明,用活疫苗替代灭活疫苗,同时实现高疫苗接种覆盖率,增强了群体效应,有助于更好地控制培训中心的 EHV-1 流行。